Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:
MF Tracker: Can this top performing smallcap fund keep winning streak alive?
Bandhan Small Cap Fund has delivered impressive returns, outperforming its benchmark and category averages over multiple periods. Fund manager changes and strategic sector allocation contributed
April 7, 2025